General fitness, health and nutrition · Public discussion

Lactoferrin / Bone Marrow Transplant

Started by Email address hidden · · Last activity · 2 posts · 267 views

Thread details

What we know about this thread

Original section
General fitness, health and nutrition
Published
30 December 2005
Last activity
30 December 2005
Original author
Email address hidden
Posts
2
Discussion status
Public discussion
Total views
267
Views / 30 days
0

The navigation and discussion metadata provide context. Posts remain in their original chronological order.

Showing posts 1–2 of 2
Posts remain in their original chronological order.

Text size
  1. <<snip>>
    Lactoferrin may be a useful agent to accelerate restoration of immune
    responsiveness
    <<snip>>

    Stem Cells and Development
    Lactoferrin Accelerates Reconstitution of the Humoral and Cellular
    Immune Response During Chemotherapy-induced Immunosuppression and Bone
    Marrow Transplant in Mice
    Oct 2005, Vol. 14, No. 5: 548-555

    J. Artym
    Department of Experimental Therapy, Institute of Immunology and
    Experimental Therapy of the Polish Academy of Sciences, Wroclaw,
    Poland.
    M. Zimecki
    Department of Experimental Therapy, Institute of Immunology and
    Experimental Therapy of the Polish Academy of Sciences, Wroclaw,
    Poland.
    J. Kuryszko
    Department of Histology and Embriology, Wroclaw Agriculture University,
    Wroclaw, Poland.
    Dr. M.L. Kruzel
    Department of Integrative Biology and Pharmacology, University of
    Texas, Health Science Center at Houston, TX 77030.
    Experimental evidence from previous studies supports the conclusion
    that orally administered lactoferrin (LF) restores the immune response
    in mice treated with a sublethal dose of cyclophosphamide (CP). The aim
    of this study was to elucidate potential benefit of LF in mice
    undergoing chemotherapy with busulfan (BU) and CP, followed by
    intravenous (i.v.) injection of bone marrow cells. CBA mice were
    treated orally with busulfan (4 mg/kg) for 4 consecutive days, followed
    by two daily doses of CP delivered intraperitoneally (i.p.) at a dose
    of 100 mg/kg and reconstituted next day with i.v. injection of 107
    syngeneic bone marrow cells. One group of these mice was given LF in
    drinking water (0.5% solution). After treatment, mice were immunized
    with ovalbumin (OVA) to subsequently measure delayed type
    hypersensitivity responsiveness and with sheep red blood cells to
    determine humoral immunity by evaluation of splenic antibody-forming
    cells. As expected, both humoral and cellular immune responses of mice
    that were treated with these chemotherapeutic agents was markedly
    impaired. Here we report that this impairment was remarkably attenuated
    by oral administration of LF. Humoral immunity fell to levels that were
    66-88% lower than that of untreated animals. Humoral immunity of
    LF-treated animals was equivalent to that of untreated mice within 1
    month. Cellular immune responses were inhibited by chemotherapy
    treatment to a lesser degree, reaching levels that were approximately
    50% lower than those of untreated animals. Again, LF mitigated this
    decrease, resulting in responses that were only slightly lower than
    those observed in untreated animals. Furthermore, when mice were given
    a lethal dose of BU (4 × 25 mg daily doses, i.p.) followed by a bone
    marrow transplant, LF caused enhanced lympho-, erythro-, and
    myelopoiesis in the bone marrow and appearance of transforming splenic
    lymphoblasts, similar to effects caused by administration of
    recombinant human granulocyte-macrophage colony-stimulating factor
    (GM-CSF). In summary, our study suggests that LF may be a useful agent
    to accelerate restoration of immune responsiveness induced by
    chemotherapy in bone marrow transplant recipients

    Who loves ya.
    Tom

    Jesus Was A Vegetarian!
    http://jesuswasavegetarian.7h.com

    Man Is A Herbivore!
    http://pages.ivillage.com/ironjustice/manisaherbivore

    DEAD PEOPLE WALKING
    http://pages.ivillage.com/ironjustice/deadpeoplewalking

  2. Pharming Announces GRAS Filing on Human Lactoferrin
    LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- 12/29/2005 -- Biotech
    company Pharming Group N.V. ("Pharming" or "the Company"😉 (Euronext:
    PHARM) (PHARM.AS) announced today that it has completed its human
    lactoferrin (hLF) filing for a Generally Recognized as Safe (GRAS)
    notification with the US Food and Drug Administration (FDA).

    Pharming has notified the FDA that its hLF is generally recognized as
    safe for use as an ingredient in functional foods. Pharming's hLF GRAS
    notification has been reviewed by an independent scientific expert
    panel. After careful evaluation of numerous safety studies performed
    with Pharming's hLF as well as of published scientific data, the expert
    panel has concluded that hLF is safe for its intended uses.

    "Pharming is pleased with the progress on the development of hLF," said
    Dr. Francis Pinto, CEO of Pharming. "The Company is in a strong
    position to execute commercial agreements and is ready for a new phase
    of rapid corporate growth."

    Background on Pharming Group N.V.

    Pharming Group N.V. is developing innovative protein products for unmet
    needs. The Company's products include potential treatments for genetic
    disorders, specialty products for surgical indications, intermediates
    for various applications and food products. Pharming has two products
    in late stage development - recombinant human C1 inhibitor for
    hereditary angioedema (Phase III) and recombinant human lactoferrin for
    use in functional foods. The advanced technologies of the Company
    include innovative platforms for the production of protein
    therapeutics, as well as technology and processes for the purification
    and formulation of these products. Additional information is available
    on the Pharming website, http://www.pharming.com.

    This press release contains forward-looking statements that involve
    known and unknown risks, uncertainties and other factors, which may
    cause the actual results, performance or achievements of the Company to
    be materially different from the results, performance or achievements
    expressed or implied by these forward-looking statements. The press
    release also appears in Dutch. In the event of any inconsistency, the
    English version will prevail over the Dutch version.

    --------------------------------------------------------------------------------

    Contact:

    Carina Hamaker
    Investor Voice
    T: +31 (0)6 537 49959
    T: +31 (0)71 524 7431

    Sarah MacLeod
    Financial Dynamics
    T: +44 (0)20 7269 7148
    T: +44 (0)7747 602 739

    Samir Singh
    Pharming Group N.V.
    T: +1 908 720 6224
    T: +1 800 333 1476

    SOURCE: Pharming

    Who loves ya.
    Tom

    Jesus Was A Vegetarian!
    http://jesuswasavegetarian.7h.com

    Man Is A Herbivore!
    http://pages.ivillage.com/ironjustice/manisaherbivore

    DEAD PEOPLE WALKING
    http://pages.ivillage.com/ironjustice/deadpeoplewalking

Active in the last 60 minutes

Active in this thread

0 users · 0 guests ·0 bots ·0 total

No signed-in users are active right now.

No known search crawlers active right now.